Skip to main content
Top
Published in: Familial Cancer 4/2010

01-12-2010

Can a phenotype for recessive inheritance in breast cancer be defined?

Authors: Carolina Ellberg, Göran Jönsson, Håkan Olsson

Published in: Familial Cancer | Issue 4/2010

Login to get access

Abstract

While a dominant inheritance of breast cancer (vertical inheritance) is well known, less is known about a possible recessive inheritance (horizontal inheritance). In a clinical series of 1676 breast cancer patient’s family history was scored as vertical (grandmother-aunt-mother-sister-daughter) or horizontal (sister-sister) and related to histopathological tumor type, presence of germline mutations, bilaterality, multifocality, screening, parity, hormone replacement therapy (HRT) use and age at diagnosis. Prognosis was estimated by also adding tumor size, lymph node status, distant metastases and hormone receptor status at diagnosis into a Cox proportional hazard model. Excluding mutations carriers, a horizontal family history (5% of all cases) was significantly associated with tubular tumor type [OR = 3.87(1.44–10.41)]. A vertical family history (23% of all cases) was significantly related to tumor multifocality [OR = 2.30(1.51–3.50)], tumor bilaterality [OR = 2.08(1.44–3.00)] and screening detection [OR = 1.50(1.10–2.05)]. No significant difference in survival could be seen between patients with none, horizontal or vertical family history. However, germline mutation carriers (BRCA1/2, TP53 or CDKN2A, present in 0.95% of the cases) had a significantly worse survival. Screening detected cases, HRT ever users and patients with estrogen receptor positive tumors had a significantly better survival adjusting for age at diagnosis, tumor size, lymph node status and presence of distant metastases at diagnosis. Factors associated with a horizontal family history were found, defining a possible phenotype for a recessive inheritance: tubular breast cancer.
Literature
1.
go back to reference O’Brien JM (2000) Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland, by P. Lichtenstein, N.V. Holm, P.K. Verkasalo, A. Iliadou, J. Kaprio, M. Koskenvuo, E. Pukkala, A. Skytthe, and K. Hemminki. N Engl J Med 343:78–84, 2000. Surv Ophthalmol 45(2):167–168CrossRefPubMed O’Brien JM (2000) Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland, by P. Lichtenstein, N.V. Holm, P.K. Verkasalo, A. Iliadou, J. Kaprio, M. Koskenvuo, E. Pukkala, A. Skytthe, and K. Hemminki. N Engl J Med 343:78–84, 2000. Surv Ophthalmol 45(2):167–168CrossRefPubMed
2.
go back to reference Peto J, Mack TM (2000) High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 26(4):411–414CrossRefPubMed Peto J, Mack TM (2000) High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 26(4):411–414CrossRefPubMed
3.
go back to reference Easton DF (1999) How many more breast cancer predisposition genes are there? Breast Cancer Res 1(1):14–17CrossRefPubMed Easton DF (1999) How many more breast cancer predisposition genes are there? Breast Cancer Res 1(1):14–17CrossRefPubMed
4.
go back to reference Ripperger T, Gadzicki D, Meindl A, Schlegelberger B (2009) Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet 17(6):722–731CrossRefPubMed Ripperger T, Gadzicki D, Meindl A, Schlegelberger B (2009) Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet 17(6):722–731CrossRefPubMed
5.
go back to reference Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40(1):17–22CrossRefPubMed Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40(1):17–22CrossRefPubMed
6.
go back to reference Athma P, Rappaport R, Swift M (1996) Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 92(2):130–134CrossRefPubMed Athma P, Rappaport R, Swift M (1996) Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 92(2):130–134CrossRefPubMed
7.
go back to reference Goldstein AM, Amos CI (1990) Segregation analysis of breast cancer from the cancer and steroid hormone study: histologic subtypes. J Natl Cancer Inst 82(24):1911–1917CrossRefPubMed Goldstein AM, Amos CI (1990) Segregation analysis of breast cancer from the cancer and steroid hormone study: histologic subtypes. J Natl Cancer Inst 82(24):1911–1917CrossRefPubMed
8.
go back to reference Amos CI, Goldstein AM, Harris EL (1991) Familiality of breast cancer and socioeconomic status in blacks. Cancer Res 51(7):1793–1797PubMed Amos CI, Goldstein AM, Harris EL (1991) Familiality of breast cancer and socioeconomic status in blacks. Cancer Res 51(7):1793–1797PubMed
9.
go back to reference Ciske DJ, Rich SS, King RA et al (1996) Segregation analysis of breast cancer: a comparison of type-dependent age-at-onset versus type-dependent susceptibility models. Genet Epidemiol 13(4):317–328CrossRefPubMed Ciske DJ, Rich SS, King RA et al (1996) Segregation analysis of breast cancer: a comparison of type-dependent age-at-onset versus type-dependent susceptibility models. Genet Epidemiol 13(4):317–328CrossRefPubMed
10.
go back to reference Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D (2001) Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 21(1):1–18CrossRefPubMed Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D (2001) Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 21(1):1–18CrossRefPubMed
11.
go back to reference Kaufman DJ, Beaty TH, Struewing JP (2003) Segregation analysis of 231 Ashkenazi Jewish families for evidence of additional breast cancer susceptibility genes. Cancer Epidemiol Biomarkers Prev 12(10):1045–1052PubMed Kaufman DJ, Beaty TH, Struewing JP (2003) Segregation analysis of 231 Ashkenazi Jewish families for evidence of additional breast cancer susceptibility genes. Cancer Epidemiol Biomarkers Prev 12(10):1045–1052PubMed
12.
go back to reference Anderson E, Berg J, Black R et al (2008) Predicting breast cancer risk: implications of a “weak” family history. Fam Cancer 7(4):361–366CrossRefPubMed Anderson E, Berg J, Black R et al (2008) Predicting breast cancer risk: implications of a “weak” family history. Fam Cancer 7(4):361–366CrossRefPubMed
13.
go back to reference Olsson HL (2009) Lobular breast carcinoma as a possible candidate phenotype for recessively inherited breast cancer. Cancer Res 69(2):119S–S Olsson HL (2009) Lobular breast carcinoma as a possible candidate phenotype for recessively inherited breast cancer. Cancer Res 69(2):119S–S
14.
go back to reference Li CI, Daling JR, Malone KE et al (2006) Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 15(5):946–954CrossRefPubMed Li CI, Daling JR, Malone KE et al (2006) Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 15(5):946–954CrossRefPubMed
15.
go back to reference Lagios MD, Rose MR, Margolin FR (1980) Tubular carcinoma of the breast: association with multicentricity, bilaterality, and family history of mammary carcinoma. Am J Clin Pathol 73(1):25–30PubMed Lagios MD, Rose MR, Margolin FR (1980) Tubular carcinoma of the breast: association with multicentricity, bilaterality, and family history of mammary carcinoma. Am J Clin Pathol 73(1):25–30PubMed
16.
go back to reference Jernstrom H, Frenander J, Ferno M, Olsson H (1999) Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 80(9):1453–1458CrossRefPubMed Jernstrom H, Frenander J, Ferno M, Olsson H (1999) Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 80(9):1453–1458CrossRefPubMed
17.
go back to reference Brinton LA, Richesson D, Leitzmann MF et al (2008) Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev 17(11):3150–3160CrossRefPubMed Brinton LA, Richesson D, Leitzmann MF et al (2008) Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev 17(11):3150–3160CrossRefPubMed
18.
go back to reference Tabar L, Dean PB (2003) Mammography and breast cancer: the new era. Int J Gynaecol Obstet 82(3):319–326CrossRefPubMed Tabar L, Dean PB (2003) Mammography and breast cancer: the new era. Int J Gynaecol Obstet 82(3):319–326CrossRefPubMed
Metadata
Title
Can a phenotype for recessive inheritance in breast cancer be defined?
Authors
Carolina Ellberg
Göran Jönsson
Håkan Olsson
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2010
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-010-9355-4

Other articles of this Issue 4/2010

Familial Cancer 4/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine